Article

Aflibercept Outperforms Ranibizumab in Cases of Serous Pigment Epithelium Detachment from Neovascular AMD

Author(s):

An optical coherence tomography study found that, after three monthly treatments,aAflibercept was 7 times more effective than ranibizumab in resolving serous pigment epithelium detachment, though neither treatment improved visual acuity in these patients to a statistically significant degree.

aflibercept, age-related macular degeneration, anti-vascular endothelial growth factor agents, best corrected visual acuity, central foveal thickness, external limiting membrane, Aflibercept, fibrovascular, hyper-reflective dots, inner segment, intraretinal fluid, intravitreal injection, length, Ranibizumab, ophthalmology, optical coherence tomography, outer segment, pigment epithelium detachment, ranibizumab, serous pigment epithelium detachment, subretinal fluid, treatment-naïve, visual acuity

A team of researchers at the Department of Ophthalmology at A University Hospital in Busan, South Korea, studied 63 patients with neovascular age-related macular degeneration (nAMD) to assess the differences in optical coherence tomography (OCT) findings between patients treated with aflibercept and those treated with ranibizumab.

These treatment-naïve patients received an intravitreal injection of aflibercept or ranibizumab once monthly for 3 months. For each treatment group, the team compared findings during baseline OCT with OCT findings after treatment. The team published the results of their study in a special issue of Acta Ophthalmologica containing abstracts of the 2016 European Association for Vision and Eye Research Conference.

  • OCT findings of interest included the following:
  • Serous pigment epithelium detachment
  • Fibrovascular pigment epithelium detachment
  • Subretinal fluid
  • Intraretinal fluid
  • Dense zone of the outer retina
  • Classic neovascularization
  • Hyper-reflective dots.

The team also compared baseline and post-treatment values between the two treatment groups with respect to the following:

  • Best corrected visual acuity (BCVA)
  • Inner segment/outer segment (IS/OS) length
  • External limiting membrane (ELM) length
  • Central foveal thickness

The team noted no statistically significant differences between the two groups before treatment. However, after treatment, a significant difference in the rate of disappearance of serous pigment epithelium detachment was found between the aflibercept group and the ranibizumab group (36% vs. 5%, respectively, P = 0.02).

The team found no significant differences between treatment groups in changes from before treatment to after treatment in other OCT findings or in BCVA.

These findings led the team to conclude that aflibercept might be more effective than ranibizumab specifically for the treatment of nAMD patients with serous pigment epithelium detachment.

In addition, because they found no statistically significant improvement in visual acuity after either treatment in patients with serous pigment detachment in this study, they recommended further study of the relation between visual acuity and improvement in serous pigment detachment.

Related Coverage:

End-Stage Renal Disease Elevates Risk of Macular Degeneration

Central Foveal Thickness Cut-off Value Identified for Corticosteroid Treatment in Intermediate Uveitis

In Neovascular Age-Related Macular Degeneration, Lucentis and Eylea Yield Similar Injection Burden

Related Videos
A panel of 3 experts on dry eye
A panel of 3 experts on RVO
HCPLive Five at ASRS 2024 | Image Credit: HCPLive
Jordana Fein, MD: Pre-Dose IOP Outcomes After Aflibercept 8 mg for DME | Image Credit: LinkedIn
Diana Do, MD: Impact of Baseline BCVA on Aflibercept 8 mg Outcomes in DME | Image Credit: Stanford University
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
© 2024 MJH Life Sciences

All rights reserved.